A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.

开始日期2024-09-01

申办/合作机构

Eli Lilly & Co.

NCT06440980 / Recruiting临床1期

A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated.
The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

开始日期2024-06-24

申办/合作机构

Eli Lilly & Co.

NCT06370728 / Completed临床1期

A Drug-Drug Interaction Study to Assess the Effect of Carbamazepine on the Pharmacokinetics of Orforglipron in Healthy Participants

The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.

开始日期2024-05-06

申办/合作机构

Eli Lilly & Co.

100 项与 Orforglipron 相关的临床结果

登录后查看更多信息

100 项与 Orforglipron 相关的转化医学

登录后查看更多信息

100 项与 Orforglipron 相关的专利（医药）

登录后查看更多信息

项与 Orforglipron 相关的文献（医药）

2024-03-01·Diabetes, obesity & metabolism

Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes

Letter

作者: Haupt, Axel ; Pratt, Edward ; Robins, Deborah ; Sloop, Kyle W. ; Ma, Xiaosu ; Benson, Charles ; Liu, Rong ; Coskun, Tamer

Aim : To report the results of a Phase 1b trial evaluating the safety, pharmacokinetics and pharmacodynamics of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D).Materials and Methods : This was a double-blind, placebo-controlled Phase 1 study evaluating five different dosing regimens.The first group established that weekly dose escalation of the daily doses of orforglipron was generally well tolerated.This enabled a parallel-arm design for the four groups following.Participants were randomized 3:1 to daily doses of orforglipron or placebo for 12 wk.Eligible participants with T2D were aged 18 to 70 years and had glycated Hb (HbA1c) levels ≥53.0 mmol/mol (7.0%) and ≤91.3 mmol/mol (10.5%).Results : A total of 51 participants received orforglipron and 17 received placebo.In the placebo and orforglipron groups, resp., baseline HbA1c was 8.1% and 8.0%, and baseline body weight was 90.3 and 88.4 kg.The most common adverse events were gastrointestinal-related, and occurred early in treatment, similar to findings with other GLP-1RAs.At Week 12, mean t1/2 ranged from 29 to 49 h.Mean HbA1c change ranged from -1.5% to -1.8% across orforglipron doses, vs. -0.4% with placebo, and body weight change was -0.24 to -5.8 kg across orforglipron doses, vs. 0.5 kg with placebo.Conclusions : Orforglipron treatment resulted in meaningful reductions in HbA1c and body weight, with an adverse event profile consistent with that of other GLP-1RAs.Orforglipron may provide a safe and effective once-daily oral treatment alternative to injectable GLP-1RAs or peptide oral formulations without water and food restrictions.

2024-02-01·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis

Review

作者: Nie, Juan ; Li, Hong ; Yu, Guanzheng ; Liu, Yinbei ; Huang, Qi ; Yang, Bao ; Tu, Xing

BACKGROUND:

GLP-1 receptor agonists (GLP-1RAs) reduce glucagon and glycogen secretion, inhibit appetite and slow gastric empties and have recently been approved to treat obesity.

OBJECTIVE:

To explore the safety and efficacy of GLP-1RAs in the treatment of obesity and clarify the optimal GLP-1RAs treatment regimen.

METHODS:

PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023. Literature screening and data extraction were performed independently by three researchers. Bayesian random effect model was used to compare the effects of interventions. Continuous variables were expressed as mean difference with 95% CI, and dichotomous variables were reported as RR with 95% CI.

RESULTS:

A total of 29 studies with 10,333 participants were included in the present study. The combination of cagrilintide and semaglutide (short for cagrANDsema) was an optimal strategy for weight loss and glycosylated hemoglobin (HbA1c) reduction. Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73) and HbA1c by - 0.33% (95% CI: -0.41, -0.25). Moreover, this study indicated that orforglipron and semaglutide also had relatively good effects on weight loss. Meta-regression results indicated that higher dose levels might have better effects on weight loss.

CONCLUSIONS:

CagrANDsema exerts the best effect for weight loss. In terms of current dose levels, a higher dose gets better weight-loss effects without increasing the risk of adverse events.

2024-10-01·Current diabetes reviews

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity

Review

作者: Aliter, Hashem F. ; Al-Horani, Rami A. ; Aliter, Kholoud F.

Abstract::

Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity

237

项与 Orforglipron 相关的新闻（医药）

2024-09-17

·drugs

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30

HONG KONG, Sept. 17, 2024. Ascletis Pharma Inc. ("Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30, the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once monthly subcutaneously and once-daily orally for the treatment of obesity. Ascletis received clearance for its Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) in July 2024 for ASC30 tablets and September 2024 for ASC30 injection. The Company expects topline data from both U.S. Phase I clinical trials in the first quarter of 2025. ASC30 was discovered and developed in-house at Ascletis as a GLP-1R biased small molecule agonist without β-arrestin recruitment. ASC30 has unique and differentiated properties that enable the administration of one small molecule as both a once-monthly subcutaneous injection and a once-daily oral tablet. ASC30 has two- to threefold better in vitro potency against GLP-1R when compared head-to-head with orforglipron. In the intravenous glucose tolerant test (IVGTT) in non-human primates (NHPs), ASC30 (1.5 mg/kg dose) stimulated statistically and significantly more insulin secretion when compared head-to-head with orforglipron (6 mg/kg dose). In animal models, ASC30 injection showed a half-life of up to 25 days, supporting once-monthly injection in humans. In NHPs, a single dose of ASC30 subcutaneous injection demonstrated sustained and favorable weight loss over one month compared to six weekly doses of an antibody-peptide conjugate. ASC30 once-monthly subcutaneous injection has potentially strong competitive advantages (less frequent injections and/or lower cost of goods) against weekly injected peptide GLP-1 drugs and monthly injected antibody-peptide conjugate drug candidate. ASC30 once-daily tablets have the potential to be the best-in-class GLP-1R small molecule agonist given its superior pharmacokinetic (PK) profile and greater potency against GLP-1R. In animal models, ASC30 tablets had a half-life of up to 36 hours, supporting once-daily oral dosing. In NHPs, once-daily oral dosing of ASC30 demonstrated significant weight loss. Utilizing Ascletis' proprietary technology, the relative bioavailability of ASC30 tablets was 99% at steady state in animal models. "In obesity and diabetes markets, both once-monthly injections and oral once-daily administration are attractive to patients, who may choose to switch from injections to oral drugs or vice versa based on chronic weight management approach, lifestyle and convenience," said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. "As one small molecule, ASC30 offers both once-monthly injection and once-daily oral dosing options. Furthermore, the ASC30 oral tablet and injection offer same or similar safety profiles to enhance ease of switching between both options." Dr. Wu continued, "From our research and development efforts over the past three years, we have developed a differentiated small molecule product that is highly competitive in both the subcutaneous obesity treatment market and the oral obesity treatment market. By combining the unique properties of ASC30 and Ascletis' proprietary technology, we have successfully prolonged the half-life of ASC30 injection to 25 days, enabling once-monthly dosing. To date, the data for ASC30 subcutaneous and oral forms supports our belief that it has the potential to be a first-in-class and best-in-class GLP-1R agonist." Two ASC30 Phase I Clinical Studies for the Treatment of Obesity The Phase I study of ASC30 once-monthly subcutaneous injection is a randomized, double-blind, placebo-controlled, single ascending dose (5 cohorts) study being conducted in the U.S. to evaluate the safety, tolerability, PK and efficacy of ASC30 in participants with obesity over 16 weeks. In cohort 1, two patients with obesity have been successfully dosed with ASC30 once-monthly injection and demonstrated good safety and tolerability. The Phase I study of ASC30 once-daily tablets is a randomized, double-blind, placebo-controlled, single ascending dose (6 cohorts) and multiple ascending dose (3 cohorts, 28 daily oral doses) study being conducted in the U.S. to evaluate the safety, tolerability, PK and efficacy of ASC30 in participants with obesity. In cohort 1, all eight obese patients (six on drug and two on placebo) have been successfully dosed with ASC30 tablets and demonstrated good safety and tolerability. About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both subcutaneous injection and oral tablet administrations. ASC30 is a new molecular entity (NME), with U.S. and global compound patent protection until 2044. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis has rapidly advanced its pipeline, focusing on two therapeutic areas with unmet medical needs from a global perspective: metabolic diseases and viral diseases. Ascletis has multiple clinical stage drug candidates in its R&D pipeline. SOURCE Ascletis Pharma Inc. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床1期临床结果临床申请

2024-09-17

·BioSpace

Obesity Pill Races Heats Up as Novo, Roche and Terns Share Data

iStock, master1305 The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets. Novo Nordisk, Roche and Terns Pharmaceuticals used last week’s European Association for the Study of Diabetes annual meeting to present new data on their oral obesity candidates. After four weeks of dosing, the placebo-adjusted weight loss figures were 4% for Novo’s amycretin, 4.9% for Terns’ TERN-601 and 6.1% for Roche’s CT-996. Slotting the three candidates into a ranking of oral obesity drug candidates by placebo-adjusted weight loss after four weeks enables an early attempt to order the molecules and rival drugs by efficacy. In earlier data drops, the comparable figures were 3.2% for Viking Therapeutics’ VK2735, 3.9% for Eli Lilly’s orforglipron, 4.9% for Structure Therapeutics’ GSBR-1290 and 5.2% for Pfizer’s danuglipron. Based on the figures, Roche and Pfizer hold the top two spots, with Structure and Terns tied for third. However, it is unclear whether the figures reflect differences between the molecules or the trial designs, analysts warned, noting that these early cross-trial assessments always introduce factors that can confound attempts to compare efficacy. Roche’s Tolerability Data Disappoint While Roche saw the most weight loss, Jefferies analysts said in a note to investors that the competitive result “appears driven by rapid titration.” The fast speed at which Roche increased the doses may explain both the strong efficacy and high rates of adverse events seen in the study. Taken at face value, the data suggest CT-996 is more efficacious and less tolerable than the competition. Yet, the Jefferies analysts said the molecule’s “true competitive profile” will not be known until Roche runs larger Phase II trials, which could dial down efficacy and side effects using lower starting doses and smaller or less frequent dose increases. For now, the tolerability data are overshadowing the promising efficacy, with Roche reporting rates of nausea, diarrhea and vomiting of 83.3%, 50.0% and 33.3%, respectively, even in the less rapidly titrated cohort. BMO analysts gave their take on the figures and data on Roche’s injectable obesity candidate in a note to investors. “While Ph 1 results slightly underperformed expectations this week on tolerability, Roche is likely to remain a relevant player in obesity development, even if they are a step behind leaders like Lilly and Novo,” the analysts said. Novo Faces Manufacturing Questions Truist analysts said in a note to investors that Novo’s tolerability update on its oral amycretin “was a bit underwhelming” but that reflected the lack of positive differentiation rather than a downside versus other oral GLP-1 drugs. In addition to GLP-1, the molecule engages amylin, enabling it to act on glucose control and appetite via a different pathway than rival drug candidates, BMO analysts described. “Amylin was one of the hottest topics of the conference, with a number of presenters highlighting the importance of optionality when you are looking to treat [a] heterogeneous disease like obesity,” BMO analysts wrote. “The target offers benefits separate from and synergistic to what we have seen from the GLP-1 class.” The analysts said the molecule’s efficacy is potentially best in class but added that “given amycretin is a peptide, we would like to hear more from Novo on manufacturing.” Jefferies analysts expanded on why manufacturing could be a problem for Novo. “Based on conservative Phase I titration info, even our $5bn amycretin WW peak sales may require >30 tonnes of API p.a. if the oral route is prioritized, suggesting reformulation for greater bioavailability through tweaking SNAC technology is critical,” the analysts said. Terns’ Novel Approach Catches Attention Terns’ results were in line with the Jefferies analysts’ bull case, with the company reporting weight loss at the upper end of the spectrum achieved by rivals. Gastrointestinal side effects were common, with 88% of people reporting nausea on one dose, but more than 85% of treatment-emergent adverse events were mild. The Jefferies analysts spotted details that could differentiate Terns. “Here’s what surprised us – we think there’s a possibility [Terns] could have a dose that could thread the needle in larger trial by showing tolerability that could approach [Lilly’s orforglipron] (but too soon to say) despite a less than ideal PK/PD pro competitive 10-15% 52 week [weight loss],” the analysts said. “Interestingly, [Terns] is taking an approach we have not seen with other oral GLP-1s so far.” The analysts said the high plasma protein binding, low solubility and high gut permeability of Terns’ drug candidate means the “oral-GLP-1 is accumulating in the gut in a manner that meaningfully extends its effective exposure, pretty similar to a long-acting oral.” The pro allow Terns to give relatively high doses to maximize weight loss without causing intolerable side effects, the analysts said. However, the downsides are that the approach requires people to take lots of tablets and high doses with potential variability, the analysts said. Like its rivals, Terns needs to generate Phase II data to start to clear up the questions about its candidate.

临床1期临床结果临床2期

2024-09-13

·FierceBiotech

Biolexis enters oral GLP-1 horse race with preclinical study showing small molecule reduced weight of obese mice

Biolexis joins a crowded field of biotechs and pharmas trying to turn the booming GLP-1 weight loss drugs into a more convenient pill form rather than an injection. Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule BLX-7006 reduced the weight of obese mice by 15% over a 28-day span."We are thrilled with the positive outcomes from our preclinical studies," Biolexis chief scientific officer Hariprasad Vankayalapati, Ph.D., said in a Sept. 12 release. "Our goal is to bring forward an innovative weight loss therapy that offers the same, or better, efficacy as injectable treatments but in a more convenient oral form." Biolexis is headquartered in Levi, right in the middle of Utah. The broader area is home to Utah’s booming tech sector, known as the Silicon Slopes. Biolexis was founded in Nov. 2021 by Vankayalapati and David Bearss, Ph.D., both from the University of Utah.Next, the biotech plans to conduct IND-enabling studies and begin human clinical trials early next year, chief business officer Keith Marmer said in the release.GLP-1 agonists like BLX-7006 work by mimicking glucagon-like peptide-1 and binding to its usual receptors. This triggers the production of insulin, which helps lower blood sugar levels, and also slows the emptying of the stomach and reduces hunger. Through these combined effects, the drugs can both help treat diabetes and lead to weight loss.Biolexis joins a crowded field of biotechs and pharmas trying to turn the booming GLP-1 weight loss drugs into a more convenient pill form rather than an injection. The oral version of semaglutide, Novo Nordisk’s Rybelsus, is approved for type 2 diabetes but not for weight loss. Novo has been working to develop an oral GLP-1 agonist that matches Wegovy, its injected semaglutide for weight loss. In March, the Danish pharma reported its oral candidate amycretin had reduced weight by 13.1% after 12 weeks in a phase 1 trial.Meanwhile, Eli Lilly, maker of Zepbound (tirzepatide), has been trialing a once-daily pill called orforglipron; last year the company announced that it produced weight loss between 9% and 15% over a 36-week period, depending on the dose. Pfizer and Roche also have horses in the race, both currently moving through human trials.GLP-1 drugs have shown promise in other areas, too. For example, a recent study found that an old GLP-1 called liraglutide could potentially protect the brain from Alzheimer’s disease.

上市批准临床1期临床结果

100 项与 Orforglipron 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心血管疾病	临床3期	美国	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	阿根廷	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	奥地利	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	巴西	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	捷克	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	德国	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	希腊	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	印度	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	意大利	Eli Lilly & Co.	2023-04-03
心血管疾病	临床3期	墨西哥	Eli Lilly & Co.	2023-04-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05051579 (EASD2023)	临床2期	超重 \| 肥胖	272	Orforglipron (OFG) 12 mg	顧壓餘遞淵鬱膚鹹願壓(齋淵糧顧廠鹹願積願衊) = 衊鹽觸糧範鹹醖鏇願顧獵艱壓簾糧糧膚鑰構鹹 (蓋願餘廠衊鏇製鏇餘艱 ) 更多	积极	2023-10-03
				Orforglipron (OFG) 24 mg	顧壓餘遞淵鬱膚鹹願壓(齋淵糧顧廠鹹願積願衊) = 醖顧艱憲廠繭餘廠襯醖獵艱壓簾糧糧膚鑰構鹹 (蓋願餘廠衊鏇製鏇餘艱 ) 更多
NCT05051579 (GZGI, CTgov)	临床2期	肥胖	272	LY3502970 (24 mg LY3502970)	積獵艱鑰窪選蓋餘網顧(構鹹鏇齋選願襯選網夢) = 網製壓簾窪淵顧繭構鹹積構膚製網蓋獵簾構獵 (製廠夢製蓋憲壓顧積鑰, 餘獵蓋獵製願製製範齋 ~ 願觸願襯獵觸廠構鏇糧) 更多	-	2023-09-13
				Placebo (Placebo)	積獵艱鑰窪選蓋餘網顧(構鹹鏇齋選願襯選網夢) = 壓壓願齋鏇鬱艱製艱蓋積構膚製網蓋獵簾構獵 (製廠夢製蓋憲壓顧積鑰, 淵壓選鏇築鹽衊簾繭衊 ~ 製艱觸觸鬱壓範網願壓) 更多
NCT05048719 (ADA2023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	壓鹹積鹽遞廠鏇淵醖壓(鏇觸簾壓憲壓鬱築簾鑰) = 廠網鏇憲窪觸襯鏇壓積淵簾鬱構願製網築淵鹽 (夢顧鏇蓋蓋鹹廠積蓋鏇 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	壓鹹積鹽遞廠鏇淵醖壓(鏇觸簾壓憲壓鬱築簾鑰) = 窪蓋顧襯選鹹鏇窪淵窪淵簾鬱構願製網築淵鹽 (夢顧鏇蓋蓋鹹廠積蓋鏇 ) 更多
NCT05048719 (Literature) 人工标引	临床2期	2型糖尿病	303	orforglipron	選獵鑰齋觸顧蓋鹹齋衊(鹽範艱餘構範襯糧壓簾) = 鑰餘夢觸願壓積構艱艱鏇壓廠艱餘選窪網鹹夢 (遞構鑰鑰蓋蓋鏇鹽艱範 ) 更多	积极	2023-06-23
				Dulaglutide	選獵鑰齋觸顧蓋鹹齋衊(鹽範艱餘構範襯糧壓簾) = 蓋繭構顧獵鏇糧廠獵糧鏇壓廠艱餘選窪網鹹夢 (遞構鑰鑰蓋蓋鏇鹽艱範 ) 更多
NCT05051579 (ADA2023) 人工标引	临床2期	超重 \| 肥胖	272	Orforglipron 12 mg	簾鹽鏇鑰憲廠鑰製遞獵(夢廠鑰夢夢齋積蓋壓鑰) = 鹹齋構淵廠襯簾選鏇蓋淵製繭齋鹹膚醖夢獵蓋 (襯醖積膚醖構醖簾壓鏇 ) 更多	积极	2023-06-23
				Orforglipron 24 mg	簾鹽鏇鑰憲廠鑰製遞獵(夢廠鑰夢夢齋積蓋壓鑰) = 齋簾繭築鑰糧窪鹹蓋齋淵製繭齋鹹膚醖夢獵蓋 (襯醖積膚醖構醖簾壓鏇 ) 更多
NCT05051579 (GZGI, Pubmed)	临床2期	肥胖	272	Orforglipron 12 mg	襯艱鏇築鹹範憲製簾鏇(鏇廠遞醖積範觸範鬱餘) = 醖壓鹹築築壓廠鬱鹽築餘蓋壓觸範壓鬱壓鹹網 (窪襯壓鬱積憲窪蓋鹽網 )	-	2023-06-23
				Orforglipron 24 mg	襯艱鏇築鹹範憲製簾鏇(鏇廠遞醖積範觸範鬱餘) = 壓壓築遞鏇廠夢鏇製窪餘蓋壓觸範壓鬱壓鹹網 (窪襯壓鬱積憲窪蓋鹽網 )
ADA2023 人工标引	临床1期	-	46	Orforglipron 3mg (fasted)	鑰憲鏇壓網鑰夢淵觸鹽(憲廠繭鹹鑰衊艱範鬱蓋) = 範觸鏇鏇鹹壓窪醖願積夢獵鹹觸廠蓋糧廠觸鏇 (蓋鹽齋夢襯齋膚觸積顧 ) 更多	积极	2023-06-20
				Orforglipron 3mg (fed)	鑰憲鏇壓網鑰夢淵觸鹽(憲廠繭鹹鑰衊艱範鬱蓋) = 膚鹹廠襯膚壓獵鏇窪選夢獵鹹觸廠蓋糧廠觸鏇 (蓋鹽齋夢襯齋膚觸積顧 ) 更多
NCT04426474 (NEWS) 人工标引	临床1期	2型糖尿病	68	LY3502970	鹹壓襯艱繭醖鏇鬱選鹽(蓋襯齋廠積鏇鹹願衊繭) = 糧鬱鑰鹹膚膚蓋網鹹醖襯糧夢夢鏇簾願構膚淵 (繭醖繭構襯簾構獵觸膚 ) 更多	积极	2022-10-13
				Placebo	構選膚鹽鬱鏇構糧淵繭(鬱顧襯夢觸膚鏇衊襯鬱) = 鹽蓋觸蓋襯衊餘鹽觸艱簾選衊膚遞壓廠窪築顧 (廠壓齋製壓蓋窪獵鹽淵 ) 更多
NCT03929744 (ADA2022)	临床1期	-	133	LY3502970	選構簾窪衊憲鑰醖網鬱(繭壓遞遞襯繭齋遞觸鹹) = occurring in ≥3 subjects 鬱鏇鏇壓醖鹽積鑰鬱淵 (淵鬱簾醖簾淵淵選鬱觸 ) 更多	-	2022-06-01